Skip to content
Screener

Pre-Tax Income at other companies

Indivior Pharmaceuticals, Inc. logo
Indivior Pharmaceuticals, Inc.INDV
$115M+94.9%
ARS Pharmaceuticals, Inc. logo
ARS Pharmaceuticals, Inc.SPRY
-$42.84M-2,168%
Viatris logo
ViatrisVTRS
-$64M+70.5%
AMP
Amphastar PharmaceuticalsAMPH
$38.54M-2.0%
AbbVie logo
AbbVieABBV
$4.28B+175%
Avalo Therapeutics logo
Avalo TherapeuticsAVTX
-$36.34M-75.1%

Segments

By segment

See full
Reportable Segment-$22.86M-68.8%

Other financials

Income statement

See full
Revenue$13.8M+38.1%
Gross profit$9.8M+80.1%
Operating income-$8.2M+27.7%
Net income-$22.9M-68.8%
EPS (diluted)-$0.18-28.6%

Balance sheet

See full
Cash & equivalents$98.5M+62.7%
Total debt$63.4M+6.0%
Total equity-$56.6M+22.0%
Total assets$132.1M+41.0%

Cash flow

See full
Operating cash flow-$9.4M-19.3%
CapEx$212.0K+98.1%
Free cash flow-$9.7M-20.3%

Valuation

See full
Market cap$538.25M+40.4%
Enterprise value$503.14M+31.5%
P/S10×+1.3×

Profitability

See full
Gross margin67%+5.9pp
Operating margin-97.5%-15.0pp
Net margin-144.6%-2.6pp
FCF margin-85%-17.0pp

Returns & leverage

See full
Return on equity121.1%
Debt / equity-1.1×
Current ratio7.2×+3.7×

Where this comes from

Reported directly by Aquestive Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest.

The source filing: Aquestive Therapeutics, Inc.’s 10-Q, filed August 11, 2026.

Filed
Aug 11, 2026, 4:10 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001398733-26-000042
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Interest expense related to royalty obligations(972)(1,434)(1,945)(2,871)
Interest expense related to the sale of future revenue(61)(61)(121)(120)
Interest income and other income, net8822,0969652,809
Net loss before income taxes(22,864)(13,548)(30,921)(36,478)
Net loss$(22,864)$(13,548)$(30,921)$(36,478)
Comprehensive loss$(22,864)$(13,548)$(30,921)$(36,478)
Loss per share attributable to common stockholders:
Basic and diluted (in dollars per share)$(0.18)$(0.14)$(0.25)$(0.37)

Item 1. FINANCIAL STATEMENTS (Unaudited)

FAQ

What is Aquestive Therapeutics, Inc.'s pre-tax income?
Aquestive Therapeutics, Inc. (AQST) reported pre-tax income of -$22.86M in Q2 2026.
How has Aquestive Therapeutics, Inc.'s pre-tax income changed year-over-year?
Aquestive Therapeutics, Inc.'s pre-tax income decreased by 68.8% year-over-year, from -$13.55M to -$22.86M.
What is the long-term trend for Aquestive Therapeutics, Inc.'s pre-tax income?
Over 4 years (2021 to 2025), Aquestive Therapeutics, Inc.'s pre-tax income has grown at a 4.4% compound annual growth rate (CAGR), from -$70.54M to -$83.78M.
What does pre-tax income mean?
Total income from all sources — operating income plus non-operating items like interest income, investment gains, and other income — before the provision for income taxes.

Ask your AI about Aquestive Therapeutics, Inc.'s pre-tax income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude